Abstract
Monoclonal antibody therapy has been approved for prophylaxis and treatment of severe COVID-19 infection. Greatest benefit appears limited to those yet to mount an effective immune response from natural infection or vaccination, but concern exists around ability to make timely assessment of immune status of community-based patients where laboratory-based serodiagnostics predominate. Participants were invited to undergo paired laboratory-based (Abbott Architect SARS-CoV-2 IgG Quant II chemiluminescent microparticle immunoassay) and lateral flow assays (LFA; a split SARS-CoV-2 IgM/IgG and total antibody test) able to detect SARS-CoV-2 anti-spike antibodies. LFA band strength was compared with CMIA titer by log-linear regression. Two hundred individuals (median age 43.5 years, IQR 30-59; 60.5% female) underwent testing, with a further 100 control sera tested. Both LFA band strengths correlated strongly with CMIA antibody titers (P < 0.001). LFAs have the potential to assist in early identification of seronegative patients who may demonstrate the greatest benefit from monoclonal antibody treatment.
Keywords: COVID-19; Lateral flow assay; Monoclonal antibody.
【저자키워드】 COVID-19, lateral flow assay, monoclonal antibody., 【초록키워드】 Treatment, SARS-CoV-2, immune response, vaccination, antibody, monoclonal antibody therapy, Prophylaxis, lateral flow, immunoassay, CMIA, IgM/IgG, sera, female, Patient, Antibody titer, Antibody test, natural infection, SARS-CoV-2 IgG, anti-spike antibodies, monoclonal antibody treatment, Immune status, Abbott, Severe COVID-19 Infection, median age, individual, participant, Architect, Microparticle, effective, benefit, tested, detect, approved, undergo, appear, assist, correlated strongly, IQR, Lateral, log-linear regression, seronegative patient, 【제목키워드】 SARS-CoV-2, therapy, monoclonal antibody, Prophylaxis, lateral flow, anti-spike antibody, individual, feasible,